000117616 001__ 117616
000117616 005__ 20221004075926.0
000117616 0247_ $$2doi$$a10.3390/eca2022-12736
000117616 0248_ $$2sideral$$a128956
000117616 037__ $$aART-2022-128956
000117616 041__ $$aeng
000117616 100__ $$aGracia, Raquel
000117616 245__ $$aExperience of Real-Life Use of Dalbavancin as an Off-Label Treatment of Complicated Infectious Diseases in a Tertiary Care Hospital
000117616 260__ $$c2022
000117616 5060_ $$aAccess copy available to the general public$$fUnrestricted
000117616 5203_ $$aDalbavancin is a lipoglycopeptide indicated for the treatment of acute bacterial skin and skin structure infections. The aim of this study is to describe the cases in which dalbavancin has been used as an off-label use for the treatment of infections by gram-positive microorganisms. Meth-ods: we carried out a case report series study of all patients treated with dalbavancin as off-label from January 2017 to March 2022. Results: Dalbavancin was administered to seventeen patients. The most frequent diagnosis was osteoarticular infection in 52.94%of patients. The principal isolated microorganism was Staphylococcus epidermidis (47.00%). The posology of dalbavancin was highly variable and the median number of days of treatment was 14 (1–56). At 3 months of treatment only 2 patient died for others reasons and no patient had reinfection. Conclusion: dalbavancin is an an-tibiotic with a novel dosage in infectious diseases of Gram-positive that proven to be high effective because no patient manifested symptoms of reinfection.
000117616 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000117616 655_4 $$ainfo:eu-repo/semantics/conferenceObject$$vinfo:eu-repo/semantics/publishedVersion
000117616 700__ $$aArenere, Mercedes
000117616 700__ $$aBonaga, Beatriz
000117616 700__ $$aAllende, María Ángeles
000117616 700__ $$0(orcid)0000-0001-9962-3387$$aFrutos Pérez-Surio, Alberto$$uUniversidad de Zaragoza
000117616 700__ $$aSalvador, María del Tránsito
000117616 700__ $$aFresquet, Raquel
000117616 700__ $$aPascual, Oihana
000117616 700__ $$aVinuesa, José Manuel
000117616 7102_ $$11011$$2615$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Medic.Prevent.Salud Públ.
000117616 773__ $$g12, 1 (2022), [4 pp.]$$pMed. sci. forum$$tMedical sciences forum$$x2673-9992
000117616 85641 $$uhttps://sciforum.net/paper/view/12736$$zTexto completo de la revista
000117616 8564_ $$s307565$$uhttps://zaguan.unizar.es/record/117616/files/texto_completo.pdf$$yVersión publicada
000117616 8564_ $$s2513554$$uhttps://zaguan.unizar.es/record/117616/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000117616 909CO $$ooai:zaguan.unizar.es:117616$$particulos$$pdriver
000117616 951__ $$a2022-10-03-16:20:18
000117616 980__ $$aARTICLE